Attenuation of Doxorubicin-induced Hepato- and Nephrotoxicity by Proanthocyanidins from Myrica nagi Bark in Wistar Rats

Abstract

Due to dose-related toxic effects, doxorubicin, a very potent and often used anti-cancer medication, is largely limited. The current research investigated the protective impact of Myrica nagi bark (PMN)-isolated proanthocyanidins on hepato-induced doxorubicin and nephrotoxicity in Wistar rats. The animals were subdivided into six classes of five rats each. Group I got PMN (200 mg/kg, p.o.) for 21 days, Group II received Doxorubicin (DXR) (60 mg/kg, i.p.) once, 48 h before sacrifice, Group III received PMN (200 mg/kg, p.o.) for 21 days, Group IV, V, and VI received PMN (200 and 400 mg/kg, p.o.) and Limarin (25 mg/kg, p.o.) for 21 days and DXR (60 mg/kg, i.p.) once, 48 h before sacrifice, respectively. Animals were slaughtered after 21 days and blood samples were obtained for liver and kidney biomarker detection. For in-vivo antioxidant experiments, the upper liver lobe and the right kidney were dissected. There is a substantial decrease in levels of liver and kidney biomarkers in the pre-treatment of PMN in the doxorubicin-treated population. PMN substantially reversed DXR's effects on superoxide dismutase (SOD), catalase (CAT), GSH, and lipid peroxidation levels (LPO). In conclusion, data indicate that chronic administration of Myrica nagi improved DXR may have induced hepatotoxicity and nephrotoxicity via its antioxidant action.

Keywords: Doxorubicin, hepatotoxicity, Myrica nagi, nephrotoxicity, proanthocyanidins

Cite this Article

Patil Rupali A., Kasar Mayur S., Pingale Prashant L. Attenuation of Doxorubicin-induced Hepato- and Nephrotoxicity by Proanthocyanidins from Myrica nagi Bark in Wistar Rats. Research & Reviews: A Journal of Toxicology. 2020; 10(3): 19–28p.